Gold rejects a key trendline as higher oil prices and yields weigh; growth concerns remain in focusOctober 20, 2026
Share Facebook Twitter LinkedIn Pinterest Email Alvotech (ALVO) shares spiked on Tuesday after the U.S. FDA approved a new manufacturing process for Simlandi, a biosimilar the company markets with Teva Pharmaceutical (TEVA), targeting AbbVie’s (ABBV) arthritis therapy Humira (adalimumab). With the approval, the company will be permitted Source link
Gold rejects a key trendline as higher oil prices and yields weigh; growth concerns remain in focusOctober 20, 2026
Are US Treasuries still a hedge? Citi Australia CEO says the bonds are losing their edgeOctober 20, 2026
